Metastatic Castration-resistant Prostate Cancer Clinical Trials in Ann Arbor, Michigan

3 studies are recruiting for metastatic castration-resistant prostate cancer in Ann Arbor, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

    The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Michigan Hospitals, Ann Arbor, Michigan
    Locations
    80 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT04104776 on ClinicalTrials.gov

  2. Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

    The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Michigan, Ann Arbor, Michigan
    Locations
    6 in total
    Run by
    Syntrix Biosystems, Inc.

    See if you can join NCT06228053 on ClinicalTrials.gov

  3. ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

    This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. Th…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
    Locations
    31 in total
    Run by
    Zenith Epigenetics

    See if you can join NCT04986423 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.